Question 1
A patient with chronic obstructive pulmonary disease (COPD) is prescribed ipratropium. Ipratropium works by:
- A. Relaxing bronchial smooth muscle by stimulating beta-2 adrenergic receptors
- B. Inhibiting the enzyme that breaks down acetylcholine in the lungs
- C. Blocking muscarinic receptors in the airways
- D. Inhibiting the release of histamine from mast cells
Show answer and rationale
Correct answer: C — Blocking muscarinic receptors in the airways
The correct answer is C: Blocking muscarinic receptors in the airways. Ipratropium is an anticholinergic medication that works by blocking muscarinic receptors, leading to bronchodilation in patients with COPD. This mechanism of action reduces bronchoconstriction and improves airflow. A: Relaxing bronchial smooth muscle by stimulating beta-2 adrenergic receptors is incorrect because ipratropium does not act on beta-2 adrenergic receptors. B: Inhibiting the enzyme that breaks down acetylcholine in the lungs is incorrect as ipratropium does not affect the breakdown of acetylcholine. D: Inhibiting the release of histamine from mast cells is incorrect because ipratropium does not target histamine release. In summary, the correct answer is C because ipratropium's mechanism of action involves blocking muscarinic receptors to achieve bronchodilation in COPD patients